Protalix Shares Dive Over EMA's Negative Take on Elfabrio's New Dosing Plan

Protalix BioTherapeutics Inc (NYSE American: PLX) experienced a sharp selloff Friday morning, with premarket sessions showing a 20.8% drop after the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on a proposed new dosing schedule for its Fabry disease treatment, Elfabrio.

This alternative dosing regimen suggested a 2 mg/kg infusion every four weeks, as opposed to the current approved dose of 1 mg/kg every two weeks. The company based this proposal on data from its BRIGHT study and ongoing extension trials, spanning about six years, along with modeling and exposure-response analysis from prior trials.

However, the CHMP wasn't convinced that these data demonstrated comparable efficacy between the proposed and existing dosing schedules, ultimately turning down the application. This puts a stumbling block in front of what could have been a less burdensome treatment routine for Fabry disease patients.

Despite the setback, Protalix and its partner Chiesi Global Rare Diseases emphasized their commitment to improving patient convenience. Elfabrio is made through Protalix's unique ProCellEx plant-based protein expression platform, adding an innovative twist to enzyme replacement therapies.

Chiesi's Giacomo Chiesi expressed disappointment but acknowledged the cooperation throughout the regulatory process, highlighting the ongoing collaboration across researchers, patients, and regulators. Dror Bashan, Protalix's CEO, echoed a similar sentiment, stressing that easing patient treatment loads remains a key goal.

The two companies seem geared up to keep working on solutions for the Fabry community but will have to revisit their strategy after this regulatory hurdle. For now, Protalix's stock is reflecting uncertainty tied to this negative regulatory news, underscoring how critical approval dynamics remain for biotech plays reliant on narrow indications.

To put numbers on it, shared data included in the studies weren't enough to convince the CHMP of similar effectiveness, despite the length and scope. It's a reminder that regulatory bodies demand robust and indubitable proof when it comes to adjusting treatment protocols, especially in rare diseases.

It's a sharp dive but not an uncommon story in biotech - regulatory feedback can pivot a company's outlook overnight. Whether Protalix will come back with additional data or pivot approaches remains to be seen, but for now, the markets are clearly skeptical.